Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Information source: Charite University, Berlin, Germany
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malignancy; Allogeneic Stem Cell Transplantation
Intervention: Levofloxacin (Drug)
Phase: Phase 2/Phase 3
Status: Recruiting
Sponsored by: Charite University, Berlin, Germany Official(s) and/or principal investigator(s):
Igor Wolfgang Blau, Dr., Study Chair, Affiliation: Charite, CBF, Berlin, Germany
Overall contact:
Igor Wolfgang Blau, Dr., Phone: 0049 30 8445 4430, Email: igor.blau@charite.de
Summary
The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial
infections in the postneutropenic period in patients who have undergone allogeneic stem cell
transplantation (SCT).
Clinical Details
Official title: Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells
Study design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Allogeneic SCT
- Postneutropenic period
- Written consent
Exclusion Criteria:
- Fever
- Antibiotic therapy
- Neutropenia
- Refusal by the patient
Locations and Contacts
Igor Wolfgang Blau, Dr., Phone: 0049 30 8445 4430, Email: igor.blau@charite.de
Charite, CBF, Berlin 12200, Germany; Recruiting
Igor Wolfgang Blau
Additional Information
Last updated: November 29, 2007
|
